Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Registry for Belzutifan in the Treatment of Von Hippel-Lindau (VHL) Disease

NCT07554508 is registered in ClinicalTrials.gov with Chinese University of Hong Kong as lead sponsor.

NCT NCT07554508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07554508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Registry for Belzutifan in the Treatment of Von Hippel-Lindau (VHL) Disease
Lead sponsor
Chinese University of Hong Kong
Phase
Observational
Overall status
Not yet recruiting
Start date
May 31, 2026
Completion date
March 31, 2029
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

vhl - von hippel-lindau syndrome